# Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Source: https://onco.cc/trials/nct05502913/  
OnCo record `nct05502913` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Soroka University Medical Center, now recruiting.

## Summary

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer is a phase 2, randomised interventional study registered as NCT05502913 by Soroka University Medical Center, with a registry enrolment figure of 80 participants, started 2023-09-01 and due to reach its primary completion in 2025-06-30. Interventions recorded: Antibiotics; FMT (Fecal Microbiota Transplantation). Conditions listed: Metastatic Lung Cancer. Primary outcome: Progression-free Survival (PFS). Sites: Israel. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05502913
- Phase: 2
- Setting: Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer
- Sponsor: Soroka University Medical Center
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05502913: https://clinicaltrials.gov/study/NCT05502913

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05502913.json